Biomarker & Genomic Testing

PSA Screening Prostate Cancer Evidence Review

George Padron
Oncology Care, Biomarker & Genomic Testing, GU Cancers | Jun 20, 2026
An updated Cochrane review of almost 800,000 men finds PSA screening likely reduces prostate cancer deaths, about one per 500 invited, set against overdiagnosis risk.

Consumer Genomics Seeks to Link Genetic Information with Medical Records

George Padron
Precision Medicine, Biomarker & Genomic Testing, Healthcare Headlines | May 19, 2026
23andMe partners with HealthEx to integrate genetic data with medical records and lifestyle inputs, offering an AI-written health summary to 30,000 beta users.

Genetics Over Half of Contribution to Longevity

Sonia Reyes
Oncology Care, Biomarker & Genomic Testing, Healthcare Headlines, Cardiovascular Health, Neurology & CNS Disorders | Jan 30, 2026
Weizmann Institute scientists calculated genetic contribution to longevity at 55%, double previous estimates, after removing historical mortality confounders

CMS Implements Risk-Based Gene Therapy Contracting Model for State Medicaid Programs

George Padron
Medicare/Medicaid Updates, Financial Assistance Programs, Biomarker & Genomic Testing, Specialty Medicine, Policy & Legislation, Reimbursement Changes | Jan 29, 2026
The federal risk-based payment model for $2.2-3.1M sickle cell gene therapies establishes a precedent as 33 states adopt a performance accountability framework.

Payers Explore Risk Pooling Solutions for High-Cost Cell and Gene Therapy Coverage

George Padron
Prior Authorization & Appeals, Biomarker & Genomic Testing, Specialty Medicine, Reimbursement Changes | Jan 6, 2026
Insurers and employers collaborate on risk pooling solutions for cell and gene therapies costing up to $3 million, with outcomes-based agreements being tested.